Skip to contentE
Estrella Immunopharma, Inc.
E
ESLAWEstrella Immunopharma, Inc. Released Aug 13, 2026, after the close
10-Q filed Aug 13, 2026, 44 days after period end · 0001213900-26-089215
Q2 2026 · 10-Q
Revenue—
Net Income-$2.31M-$2.31MN/M vs Q2 2025N/M vs Q1 2026 EPS Diluted
No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Estrella Immunopharma, Inc. · CIK 1844417 · Engraved from SEC EDGAR
-$0.05-$0.05N/M vs Q2 2025N/M vs Q1 2026 Operating Income-$2,084,247N/M Operating Cash Flowderived-$1,780,738N/M Filing lag
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end